Latest filings (excl ownership)
10-K/A
2020 FY
Annual report (amended)
13 Apr 22
10-K
2020 FY
Annual report
30 Mar 22
10-Q
2020 Q3
Quarterly report
27 Oct 21
10-Q
2020 Q2
Quarterly report
17 Sep 21
10-Q
2020 Q1
Quarterly report
3 Sep 21
8-K/A
Changes in Registrant's Certifying Accountant
9 Aug 21
8-K
Changes in Registrant's Certifying Accountant
5 Aug 21
8-K
Gene Biotherapeutics Announces Director Retirement
28 Jul 21
8-K
Gene Biotherapeutics Partners with Fujifilm Diosynth
26 Apr 21
10-K
2019 FY
Annual report
23 Apr 21
8-K
Gene Biotherapeutics Secures Investment from Nostrum Pharmaceuticals, LLC
28 May 20
8-K
Gene Biotherapeutics Announces Director Retirement
20 Mar 19
NT 10-Q
Notice of late quarterly filing
4 Dec 18
8-K
Gene Biotherapeutics Announces Sale of Excellagen Technology
13 Sep 18
NT 10-Q
Notice of late quarterly filing
16 May 18
8-K
Taxus Cardium Announces Name
9 Jan 18
NT 10-Q
Notice of late quarterly filing
15 Nov 17
NT 10-Q
Notice of late quarterly filing
15 Aug 17
10-K
2016 FY
Annual report
28 Jul 17
10-Q
2017 Q1
Quarterly report
28 Jul 17
NT 10-Q
Notice of late quarterly filing
16 May 17
NT 10-K
Notice of late annual filing
30 Mar 17
10-Q
2016 Q3
Quarterly report
21 Mar 17
10-Q
2016 Q2
Quarterly report
6 Mar 17
10-Q
2016 Q1
Quarterly report
1 Mar 17
8-K
Regulation FD Disclosure
10 Jan 17
8-K
Regulation FD Disclosure
5 Jan 17
8-K
Angionetics to Present at Two San Francisco-based Healthcare
4 Jan 17
10-K
2015 FY
Annual report
29 Dec 16
8-K
Taxus Cardium Announces Two Director Retirements
14 Dec 16
NT 10-Q
Notice of late quarterly filing
15 Nov 16
10-Q
2015 Q3
Quarterly report
27 Oct 16
8-K
Entry into a Material Definitive Agreement
3 Oct 16
8-K
Entry into a Material Definitive Agreement
27 Sep 16
8-K
Other Events
13 Sep 16
10-Q
2015 Q2
Quarterly report
29 Aug 16
NT 10-Q
Notice of late quarterly filing
16 Aug 16
8-K
Angionetics & a Huapont Life Sciences Affiliate Enter Agreement
11 Jul 16
8-K
Entry into a Material Definitive Agreement
11 Jul 16
NT 10-Q
Notice of late quarterly filing
16 May 16
Latest ownership filings
SC 13G/A
Jemapete Christopher J
3 Feb 23
SC 13G/A
SABBY MANAGEMENT, LLC
5 Jan 22
SC 13G
Jemapete Christopher J
28 Apr 21
4
Christopher J Jemapete
28 Apr 21
4
Christopher J Jemapete
18 Mar 21
SC 13D/A
Jemapete Christopher J
18 Mar 21
SC 13D
Jemapete Christopher J
1 Mar 21
3
Christopher J Jemapete
1 Mar 21
SC 13G
Coluccio Christian F
22 Dec 20
3
NIRMAL MULYE
17 Aug 20
3
James L Grainer
14 Aug 20
3
Kaushik K. Vyas
8 Jul 20
3
Ronald J. Shebuski
8 Jul 20
3
Initial statement of insider ownership
1 Jun 20
SC 13D
Nostrum Pharmaceuticals, LLC
1 Jun 20
SC 13D
Beneficial ownership report
22 Jan 19
SC 13G/A
Taxus Cardium Pharmaceuticals Group Inc.
4 Jan 18
SC 13G/A
Taxus Cardium Pharmaceuticals Group Inc.
5 Jan 17
SC 13G/A
Taxus Cardium Pharmaceuticals Group Inc.
5 Jan 16
4
Edward W Gabrielson
27 Mar 15
4
Lon E Otremba
27 Mar 15
4
MURRAY H HUTCHISON
27 Mar 15
4
Andrew M Leitch
27 Mar 15
4
CHRISTOPHER J REINHARD
27 Mar 15
4
GERALD J LEWIS
27 Mar 15
SC 13D
Beneficial ownership report
8 Jan 15
SC 13G/A
Taxus Cardium Pharmaceuticals Group Inc.
8 Jan 15
SC 13G/A
Cardium Therapeutics, Inc.
8 Jan 14
SC 13D/A
SABBY MANAGEMENT, LLC
19 Sep 12
SC 13D
SABBY MANAGEMENT, LLC
30 Aug 12